Luminal A solid papillary breast carcinoma with lung metastasis: mastectomy and lung resection, PET-CT clear

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: Initial breast tumor and lung metastasis were ER/PR positive, HER2 0

Metastatic Site: lung

About 40 days after lung surgery, PET-CT showed no abnormalities; the specialist recommended regular follow-up without additional antitumor drug therapy, and she was alive and in good condition.

PubMed CentralRead more →

KRAS G12C lung adenocarcinoma with hypertrophic pulmonary osteoarthropathy: no recurrence after lobectomy

Patient Info: Anonymized, Male, 50s | Stage II

Biomarkers: KRAS detected; PD-L1 <1%

At 1-year follow-up, there was no evidence of recurrence; pain, edema, grip strength, and periosteal thickening related to hypertrophic pulmonary osteoarthropathy improved after surgery.

PubMed CentralRead more →

Stage IIIA KRAS p.G12V lung adenocarcinoma: pathologic complete response after chemoimmunotherapy and surgery

Patient Info: Anonymized, Female, 70+ | Stage III

Biomarkers: KRAS p.G12V mutation; PD-L1 0% tumor-cell staining; <1% tumor-associated inflammatory-cell staining; no EGFR, ALK, or ROS1 driver mutation reported

Pathology after lobectomy showed a pathologic complete response, and surveillance imaging 12 months later showed no evidence of disease recurrence.

PubMed CentralRead more →

Stage IIIA lung adenocarcinoma complicated by severe atezolizumab-induced liver toxicity

Patient Info: Anonymized, Male, 60s | Stage III

Biomarkers: PD-L1 49%; case text describes triple-negative status without expanding the specific markers

The patient was discharged clinically stable but with guarded prognosis after atezolizumab-induced vanishing bile duct syndrome, requiring prednisone, mycophenolate mofetil, ursodeoxycholic acid, prophylaxis, and close oncology/internal medicine follow-up.

PubMed CentralRead more →

Lung adenocarcinoma surgery complicated by postoperative chest wall hernia

Patient Info: Anonymized, Male, 70+

He completed VATS left lower lobectomy for lung adenocarcinoma and later mesh repair of a postoperative chest wall hernia; at 6 months after hernia repair, the hernia had not recurred.

PubMed CentralRead more →

Localized lung adenocarcinoma: lobectomy followed by air-leak repair

Patient Info: Anonymized, Male, 60s

After lobectomy and a second thoracoscopic repair for persistent postoperative air leak, the air leak resolved by postoperative day 3 and had not recurred at 2-month follow-up.

PubMed CentralRead more →

Stage 1 lung adenocarcinoma: no evidence of disease after surgery

Patient Info: Anonymized, Male, 70+

No recurrence of lung cancer or stroke at 10 months post-surgery.

PubMed CentralRead more →

Lung Adenocarcinoma Recurring Years After Surgery in a Woman With a Separate Rectal Neuroendocrine Tumor

Patient Info: Anonymized, female, 60s | Stage I

She died from progression of lung cancer about 12 years after the lung-cancer diagnosis and 13 years after the earlier rectal neuroendocrine-tumor procedure.

PubMed CentralRead more →

Stage IIIA EGFR lung adenocarcinoma: no recurrence after early osimertinib stop

Patient Info: Anonymized, Female, 70+ | Stage III

Biomarkers: EGFR exon 19 deletion mutation; elevated KL-6 and SP-D during interstitial lung disease episode

During 9 months of follow-up after osimertinib was stopped, she had no recurrence of interstitial lung disease, pulmonary embolism, or non-small cell lung cancer.

PubMed CentralRead more →

Metastatic colon cancer: soft-tissue and adrenal metastases responding to FOLFIRI plus bevacizumab

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: KRAS codon 146 mutation; BRAF wild type. CK20 and Ki-67 supported colorectal metastasis; CEA/CA19-9 were elevated.

Metastatic Site: lungs; left arm/biceps soft tissue; right…

As of May 2025, metastatic colon cancer involving soft tissue, muscle, lung history, and right adrenal gland had regressed after 12 months of FOLFIRI plus bevacizumab, and the patient was alive 1 year after chemotherapy completion.

PubMed CentralRead more →

Poorly Differentiated Lung Adenocarcinoma Without Recurrence After Surgery and Chemotherapy

Patient Info: Anonymized, male, 60s

Biomarkers: No driver mutation identified; PD-L1 at least 1%

No signs of recurrence were observed through April 2025 after surgery and 4 cycles of adjuvant chemotherapy.

PubMed CentralRead more →

Localized sarcomatoid lung carcinoma: no recurrence 14 months after lobectomy

Patient Info: Anonymized, Male, 50s

Biomarkers: No molecular biomarkers reported; histopathology confirmed sarcomatoid carcinoma

As of May 2025, the patient remained in good health with no evidence of recurrence 14 months after video-assisted thoracoscopic left lower lobectomy.

PubMed CentralRead more →

How We Got Here: 6 Young Lung Cancer Patients & Their Paths To Surgery- Part 1

Patient Info: Leah Phillips, Female | Stage IV

Biomarkers: EGFR exon 19 deletion

Metastatic Site: bone (pelvis; spine; ribs)

As of April 2025, Leah was living with Stage IV EGFR exon 19 deletion lung cancer while continuing Tagrisso after SBRT and right middle lobe lobectomy.

YouTube (JA search)Read more →

Preoperative Stage IIB lung adenocarcinoma: no recurrence after robotic surgery

Patient Info: Anonymized, Female, 60s

As of April 2025, 6-month chest CT showed no recurrence after robotic right lower lobectomy and mediastinal lymph node dissection; no additional chemotherapy or radiation was reported.

PubMed CentralRead more →

Synchronous Stage I lung adenocarcinomas: VATS surgery with clear margins

Patient Info: Anonymized, Male, 70+

He completed surgical treatment with negative lymph nodes and clear margins, was discharged on postoperative day 9, and was planned for surveillance with his respiratory physician.

PubMed CentralRead more →

Clinical Stage IB lung adenocarcinoma: no recurrence after thoracoscopic lobectomy and pneumatocele repair

Patient Info: Anonymized, Male, 60s | Stage I

Biomarkers: No molecular biomarkers reported; tumor markers were normal: CEA 2.1 ng/mL, SCC antigen 1.5 ng/mL, cytokeratin 19 fragment 0.9 ng/mL

As of March 2025, the patient had no recurrence after thoracoscopic left lower lobectomy for lung adenocarcinoma; postoperative pneumatocele-related air leak resolved with reinforcement and adhesive therapy.

PubMed CentralRead more →

EGFR-Mutant Lung Adenocarcinoma That Transformed to Small Cell Lung Cancer

Patient Info: Anonymized, female, 40s | Stage IV

Biomarkers: EGFR exon 19 deletion; acquired EGFR T790M mutation

Metastatic Site: liver

The cancer progressed after transformation to small cell lung cancer, and she died 49 months after the original diagnosis.

PubMed CentralRead more →

HER2 exon 20 metastatic lung adenocarcinoma with pathologic complete response after chemoimmunotherapy and surgery

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: HER2 exon 20 insertion lung adenocarcinoma with TP53 mutation, PD-L1 TPS 50%, and low TMB.

Metastatic Site: contralateral lung

Right lower lobectomy with radical lymphadenectomy in November 2023 showed pathologic complete response, and no additional therapy was offered after surgery.

PubMed CentralRead more →

Stage 4 lung adenocarcinoma with RET fusion responding to pralsetinib

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: RET fusion

Metastatic Site: pleura

As of March 2025, he had recovered from grade 3 Pneumocystis jirovecii pneumonia, restarted pralsetinib, and had no progressive disease or recurrence of adverse events over 13 months.

PubMed CentralRead more →

Right Middle Lobe Torsion After Surgery for Lung Adenocarcinoma

Patient Info: Anonymized, female, 60s

She recovered after the emergency second operation and was discharged in stable condition on postoperative day 6.

PubMed CentralRead more →

Stage II ALK Non-Small Cell Lung Cancer: Stephanie's Survivor Story

Patient Info: Stephanie, Female | Stage II

Biomarkers: ALK-rearranged

As of January 2025, Stephanie had clean scans and bloodwork for 3 years after Stage IIB ALK-positive lung adenocarcinoma treated with surgery, 4 rounds of chemotherapy, and ongoing daily targeted therapy.

The Patient StoryRead more →

Stage II ALK Lung Adenocarcinoma: Stephanie's Patient Story

Patient Info: Stephanie Williams, Female | Stage II

Biomarkers: ALK-rearranged

Stephanie had clean scans nearly 3 years after diagnosis but remained on daily ALK-targeted therapy to reduce recurrence risk.

The Patient StoryRead more →

Lung Cancer Surgery Followed by Severe Arm Ischemia and Amputation

Patient Info: Anonymized, female

A woman in her mid-60s underwent surgery for lung adenocarcinoma and then developed severe arterial-line-related arm ischemia that ultimately required an above-elbow amputation.

PubMed CentralRead more →

Stage IB lung adenocarcinoma: thoracoscopic lobectomy with anomalous pulmonary vein anatomy

Patient Info: Anonymized, Female, 50s | Stage I

Stage IB lung adenocarcinoma was treated with thoracoscopic left lower lobectomy and lymph-node dissection; she recovered uneventfully and was discharged on postoperative day 3.

PubMed CentralRead more →